GlobeNewswire
Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies
📊
AI Sentiment
Positive
7/10
Cognition Therapeutics Inc. News
Latest updates and market news for CGTX
1 news
Jan 26 - Feb 1, 2026
Page 1
Share this news page